Anti-LASV glycoprotein complex [25.10C], Human IgG1, kappa
Catalogue Number: AB05115-10.0-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Alias: | Lassa virus glycoprotein complex; GPC; Pre-glycoprotein polyprotein GP complex; Pre-GP-C; Stable signal peptide; SSP; Glycoprotein G1; GP1; Glycoprotein G2; GP2 |
| Shipping Condition: | Blue Ice |
| Unit(s): | 100 ug |
| Host name: | Human |
| Clone: | 25.10C |
| Isotype: | IgG1 |
| Immunogen: | The original antibody was generated from the B cells of a human survivor of Lassa fever. |
| Application: | ELISA, EM, NT, InVitroA |
Additional Text
Purification
Purified
UniProt ID
P08669
Antibody Clonality
Recombinant Monoclonal
Storage Note
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Gene ID
956585
Gene Name
LASVsSgp2
Application Notes
The original antibody (human IgG1) was generated and confirmed to specifically recognize the Lassa virus (LASV) glycoprotein complex (GPC) via ELISA. In vitro, this antibody demonstrated potent neutralizing activity against all four LASV lineages, as shown in pseudovirus assays and Plaque Reduction Neutralization Test (PRNT) (Robinson et al., 2016; PMID: 27161536). A Fab variant of this antibody was generated and tested. Cryo-EM provided insights into the neutralization mechanism-the antibody's heavy chain primarily contacts residues in GP1 (loop 225-235), essential for binding to the endosomal receptor LAMP1, while the light chain anchors to the GP2 fusion loop. By binding to these epitope sites, the antibody inhibits viral entry by blocking the interaction between LASV GP and LAMP1, preventing membrane fusion and infection. BLI characterization revealed high binding affinity, with apparent KD values of 3.52 nM, 36.1 pM, and <1.00 pM for LASV lineage I (LI) GP, the LI-R95M-GP variant, and LASV lineage IV (LIV) GP, respectively (Buck et al., 2022; PMID: 35730904). This antibody's neutralizing activity was unaffected by any of the seven glycan-knockout mutants (N99, N109, N119, N167, N224, N390, N395) on LASV GPC, as shown in the heat map of IC50 fold-changes. The Fab version of this antibody formed a stable complex with a GPCysRRLL-LPETG-1NOG trimer, as visualized by NS-EM 2D-average images and 3D-maps, confirming that it recognizes the fully cleaved, prefusion GPC trimer with native SKI-1/S1P cleavage and mammalian glycosylation (Li et al., 2022; PMID: 36288283). The original version of this antibody was used as a positive control in a pseudovirus neutralization assay alongside polyclonal antibodies generated in non-human primates and demonstrated near-complete neutralization of wild-type LASV pseudovirus (ppLASV, Josiah strain) at a low concentration (1 µg/ml) (Enriquez et al., 2025; PMID: 40168843).
AB05115-10.0 Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations